Is there an Indian version of Sotorasib?

There is no Indian version of the original drug and generic drug Sotorasib (Sotorasib) currently on the market. There are currently few treatment options for patients with KRAS G12C-mutated advanced non-small cell lung cancer whose cancer has progressed after systemic treatment with anticancer drugs, and for whom current treatments have limited effectiveness. While the main study didn't compare sotorasib to another cancer treatment, it showed the drug was effective in treating cancer, including in patients whose cancer had progressed after several different treatments.

Sotoracib is a targeted therapy that targets specific genetic mutations and is therefore only suitable for patients with theKRAS G12C mutation. It has been approved by the FDA as a first-line treatment of choice for non-small cell lung cancer in certain patients with advanced or metastatic NSCLC that cannot be surgically resected or radiotherapy. However, you should consult your doctor for personalized medical advice before using any medication. The side effects of sotoracib are considered manageable and the benefits of sotoracib outweigh its risks.

SotoracibThe original drug has not yet been launched in China, so it is not covered by medical insurance. Domestic patients cannot yet purchase this drug. The price of Hong Kong original research versionsotorasibuSpecifications120mg*240 tablets is about RMB 80,000, and the European original research version 120mg*240 tablets is priced at about RMB 44,040 (the price may fluctuate due to the exchange rate), which is relatively expensive. There are also cheaper generic drugs for sale in other countries. The specifications of the Laos Element Pharmaceutical Factory are 120mg*56 tablets and the price is around 4800 yuan (the price may fluctuate due to the exchange rate). The price is relatively cheap. The ingredients of foreign generic drugs are basically the same as the original drugs.